Neurodegenerative Disorders: Why Do We Need New Therapies?
暂无分享,去创建一个
[1] Dl Hoyert,et al. National Vital Statistics Reports NCHS.pdf , 2012 .
[2] E D Louis,et al. Mortality from Parkinson disease. , 1997, Archives of neurology.
[3] A. Danckaert,et al. Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes , 2013, Journal of Cell Science.
[4] Lewis E Kazis,et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease , 2007, BMC medicine.
[5] Nick C Fox,et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.
[6] A. Singleton,et al. TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.
[7] Z. Yue,et al. Neuronal aggregates: formation, clearance, and spreading. , 2015, Developmental cell.
[8] D. Maraganore,et al. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study , 2006, Neurology.
[9] M. Gurney,et al. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS , 1998 .
[10] O. Garaschuk,et al. Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.
[11] Hyung-Jun Kim,et al. Prion-like Mechanism in Amyotrophic Lateral Sclerosis: are Protein Aggregates the Key? , 2014, Experimental neurobiology.
[12] James Lowe,et al. Depletion of 26S Proteasomes in Mouse Brain Neurons Causes Neurodegeneration and Lewy-Like Inclusions Resembling Human Pale Bodies , 2008, The Journal of Neuroscience.
[13] A. Al-Chalabi,et al. The genetics and neuropathology of amyotrophic lateral sclerosis , 2012, Acta Neuropathologica.
[14] Steve D. M. Brown,et al. α-Synuclein impairs macroautophagy: implications for Parkinson’s disease , 2010, The Journal of cell biology.
[15] M. Freedman,et al. Increased Peroxidation and Reduced Antioxidant Enzyme Activity in Alzheimer's Disease , 1998, Experimental Neurology.
[16] C D Marsden,et al. Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.
[17] K. Jellinger,et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.
[18] D. Morens,et al. Epidemiologic observations on Parkinson's disease , 1996, Neurology.
[19] S. Wong,et al. Evidence of Inflammatory System Involvement in Parkinson's Disease , 2014, BioMed research international.
[20] Naruhiko Sahara,et al. Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.
[21] A. Mahal,et al. Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice , 2001, Neurobiology of Disease.
[22] L. Grinberg,et al. Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies , 2014, Neuron.
[23] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[24] C. Marsden,et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.
[25] C. Rebert,et al. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.
[26] D. Thurman,et al. How common are the “common” neurologic disorders? , 2007, Neurology.
[27] Chuan-en Wang,et al. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms , 2009, Proceedings of the National Academy of Sciences.
[28] Sunhong Kim,et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.
[29] D. Butterfield,et al. Brain Regional Correspondence Between Alzheimer's Disease Histopathology and Biomarkers of Protein Oxidation , 1995, Journal of neurochemistry.
[30] J. Tajti,et al. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. , 1993, Archives of neurology.
[31] G. Kollias,et al. Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia , 2006, Science.
[32] Daniel Weintraub,et al. Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. , 2008, The American journal of managed care.
[33] Changan Jiang,et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.
[34] S. Przedborski,et al. Inducible Nitric Oxide Synthase Up‐Regulation in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1999, Journal of neurochemistry.
[35] Rachelle Doody,et al. Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.
[36] W. Kukull,et al. Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[37] D. Perl,et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.
[38] Moonhee Lee,et al. Effect of overexpression of wild‐type and mutant Cu/Zn‐superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis , 2001, Journal of neurochemistry.
[39] M. Martínez-Vicente. Autophagy in neurodegenerative diseases: From pathogenic dysfunction to therapeutic modulation. , 2015, Seminars in cell & developmental biology.
[40] D. Holtzman,et al. Trans-cellular Propagation of Tau Aggregation by Fibrillar Species* , 2012, The Journal of Biological Chemistry.
[41] M. DiFiglia,et al. Huntingtin Expression Stimulates Endosomal–Lysosomal Activity, Endosome Tubulation, and Autophagy , 2000, The Journal of Neuroscience.
[42] Douglas R. McDonald,et al. A Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation , 2003, The Journal of Neuroscience.
[43] T. Dall,et al. The current and projected economic burden of Parkinson's disease in the United States , 2013, Movement disorders : official journal of the Movement Disorder Society.
[44] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[45] Osamu Yamaguchi,et al. Role of Autophagy in Aging , 2012, Journal of cardiovascular pharmacology.
[46] R. Holloway,et al. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries , 2006, Movement disorders : official journal of the Movement Disorder Society.
[47] F. Gage,et al. Mutant Huntingtin Promotes Autonomous Microglia Activation via Myeloid Lineage-determining Factors Fold Difference from the Mean , 2022 .
[48] Ronald Melki,et al. Prion-like transmission of protein aggregates in neurodegenerative diseases , 2010, Nature Reviews Molecular Cell Biology.
[49] James R. Burke,et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.
[50] Mark Ellisman,et al. MUTANT HUNTINGTIN BINDS THE MITOCHONDRIAL FISSION GTPASE DRP1 AND INCREASES ITS ENZYMATIC ACTIVTY , 2011, Nature Medicine.
[51] Weihua Zhao,et al. Microglia in ALS: The Good, The Bad, and The Resting , 2009, Journal of Neuroimmune Pharmacology.
[52] P. Massman,et al. Frontal‐lobe mediated behavioral dysfunction in amyotrophic lateral sclerosis , 2010, European journal of neurology.
[53] Ralph A. Nixon,et al. Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study , 2005, Journal of neuropathology and experimental neurology.
[54] Brian Spencer,et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.
[55] D. Cleveland,et al. Prion-like spread of protein aggregates in neurodegeneration , 2012, The Journal of experimental medicine.
[56] H. Ariga,et al. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. , 2003, Biochemical and biophysical research communications.
[57] F. Maxfield,et al. Microglial Cells Internalize Aggregates of the Alzheimer's Disease Amyloid β-Protein Via a Scavenger Receptor , 1996, Neuron.
[58] R. Mohs,et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.
[59] C. Marsden,et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.
[60] C. Zurzolo,et al. The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. , 2013, The Biochemical journal.
[61] W. Markesbery,et al. Four-Hydroxynonenal, a Product of Lipid Peroxidation, is Increased in the Brain in Alzheimer’s Disease , 1998, Neurobiology of Aging.
[62] Richard I. Morimoto,et al. Adapting Proteostasis for Disease Intervention , 2008, Science.
[63] J. Trojanowski,et al. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease , 1995, Annals of neurology.
[64] M. Tabaton,et al. Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects , 2000, Neuroscience Letters.
[65] M. Cookson,et al. α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[66] H. Gendelman,et al. Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons , 2008, PloS one.
[67] H Jick,et al. Statins and the risk of dementia , 2000, The Lancet.
[68] D. Sulzer,et al. CARGO RECOGNITION FAILURE IS RESPONSIBLE FOR INEFFICIENT AUTOPHAGY IN HUNTINGTON’S DISEASE , 2010, Nature Neuroscience.
[69] Hideyuki Okano,et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice , 2006, Nature.
[70] Françoise Condé,et al. Replicating Huntington's disease phenotype in experimental animals , 1999, Progress in Neurobiology.
[71] P. Andersen,et al. Misfolded superoxide dismutase‐1 in CSF from amyotrophic lateral sclerosis patients , 2011, Journal of neurochemistry.
[72] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[73] D. Standaert,et al. Targeted Overexpression of Human &agr;-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease , 2008, Journal of neuropathology and experimental neurology.
[74] Xinglong Wang,et al. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. , 2014, Biochimica et biophysica acta.
[75] E. Bézard,et al. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives , 2014, The Lancet.
[76] R. Albin,et al. Early autophagic response in a novel knock-in model of Huntington disease. , 2010, Human molecular genetics.
[77] Belinda Wilson,et al. Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[78] Orla Hardiman,et al. Cognitive impairment in amyotrophic lateral sclerosis , 2007, The Lancet Neurology.
[79] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[80] H. Braak,et al. Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.
[81] C. Glass,et al. The choreography of neuroinflammation in Huntington's disease. , 2015, Trends in immunology.
[82] E. Hirsch,et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. , 2008, The Journal of clinical investigation.
[83] Y. Agid,et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.
[84] S. Mckercher,et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis , 2006, Proceedings of the National Academy of Sciences.
[85] P. Brundin,et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. , 2011, The Journal of clinical investigation.
[86] E. Bézard,et al. Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys , 2014, Annals of neurology.
[87] N. Robakis,et al. Increased Expression but Reduced Activity of Antioxidant Enzymes in Alzheimer's Disease. , 1999, Journal of Alzheimer's disease : JAD.
[88] Eric Jacobs,et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease , 2005, Annals of neurology.
[89] D. Westaway,et al. Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted by Alzheimer-Related PS1 Mutations , 2010, Cell.
[90] H. Gendelman,et al. Nitrated Alpha-Synuclein and Microglial Neuroregulatory Activities , 2008, Journal of Neuroimmune Pharmacology.
[91] H. Gendelman,et al. Nitrated alpha‐synuclein‐activated microglial profiling for Parkinson’s disease , 2008, Journal of neurochemistry.
[92] D. G. Clark,et al. Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.
[93] J. Weuve,et al. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census , 2013, Neurology.
[94] Pierre N Tariot,et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.
[95] P. Ragonese,et al. Parkinson disease survival: a population-based study. , 2000, Archives of neurology.
[96] Masayuki Miura,et al. Genetic Evidence Linking Age-Dependent Attenuation of the 26S Proteasome with the Aging Process , 2008, Molecular and Cellular Biology.
[97] Jiaquan Xu,et al. Deaths: final data for 2010. , 2013, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[98] J. Trojanowski,et al. Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.
[99] Voon Wee Yong,et al. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.
[100] C. Tanner,et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.
[101] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[102] Y. Chern,et al. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease. , 2013, Human molecular genetics.
[103] R. Morimoto,et al. Integrating the Stress Response: Lessons for Neurodegenerative Diseases from C. Elegans , 2022 .
[104] Peter T. Lansbury,et al. Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.
[105] Menno P. Witter,et al. Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.
[106] David S. Park,et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[107] Ji-Yeon Shin,et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.
[108] S. Prusiner,et al. Transmission of multiple system atrophy prions to transgenic mice , 2013, Proceedings of the National Academy of Sciences.
[109] M. Hernán,et al. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease , 2006, Neurology.
[110] L. Launer. Nonsteroidal Anti-Inflammatory Drug Use and the Risk for Alzheimer’s Disease , 2012, Drugs.
[111] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[112] R. Schmid,et al. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity , 2012, Neuroscience.
[113] Brian Spencer,et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. , 2008, The Journal of clinical investigation.
[114] J. Duarte,et al. Pesticides exposure as etiological factors of Parkinson's disease and other neurodegenerative diseases--a mechanistic approach. , 2014, Toxicology letters.
[115] G. Celesia,et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.
[116] W. Willett,et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. , 2003, Archives of neurology.
[117] G. Halliday,et al. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years , 2008, Movement disorders : official journal of the Movement Disorder Society.
[118] H. Mitsumoto,et al. Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review) , 2009, Neurology.
[119] S H Appel,et al. Prevalence and patterns of cognitive impairment in sporadic ALS , 2005, Neurology.
[120] Masaaki Komatsu,et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice , 2006, Nature.
[121] K. Sakimura,et al. Motor Neuron-specific Disruption of Proteasomes, but Not Autophagy, Replicates Amyotrophic Lateral Sclerosis* , 2012, The Journal of Biological Chemistry.
[122] B. Ritz,et al. Statin use and the risk of Parkinson disease , 2008, Neurology.
[123] J. Cooper,et al. Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.
[124] K. Moore,et al. CD36 Mediates the Innate Host Response to β-Amyloid , 2003, The Journal of experimental medicine.
[125] R. Morimoto,et al. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. , 2008, Genes & development.